Autosomal recessive spastic paraplegia type 71

Autosomal recessive spastic paraplegia type 71 (SPG71) is a very rare inherited neurological condition that primarily affects the nervous system, particularly the nerves that control movement in the legs. It belongs to a group of disorders called hereditary spastic paraplegias (HSPs), which are characterized by progressive stiffness (spasticity) and weakness in the lower limbs. SPG71 is caused by mutations in the ZFR gene, which plays a role in normal nerve cell function. People with SPG71 typically develop difficulty walking due to increasing stiffness and weakness in their legs. The condition usually begins in childhood, though the exact age of onset can vary. In addition to leg spasticity, some individuals may experience intellectual disability, speech difficulties, and other neurological problems. The severity of symptoms can differ from person to person, even within the same family. There is currently no cure for SPG71. Treatment focuses on managing symptoms and maintaining quality of life. Physical therapy, stretching exercises, and medications to reduce muscle stiffness (such as baclofen or tizanidine) are commonly used. Assistive devices like braces, walkers, or wheelchairs may be needed as the condition progresses. Because SPG71 is extremely rare, research is still ongoing to better understand the disease and develop more targeted therapies.

Bring these to your next appointment

• Q1.What is the expected progression of symptoms in my child's specific case?,What therapies and medications can help manage spasticity and maintain mobility?,Should other family members be tested for carrier status?,What educational and developmental support services are available?,Are there any clinical trials or research studies we could participate in?,How often should we schedule follow-up appointments with the neurologist?,What signs should prompt us to seek urgent medical attention?

Common questions about Autosomal recessive spastic paraplegia type 71